Darzalex Faspro Injection
Product Images NDC 57894-503

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Darzalex Faspro (NDC 57894-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (15 mL Vial Box)

A Kaplan-Meier curve showing progression-free survival over months comparing two treatment groups: D-Pd and Pd. The y-axis represents the proportion surviving without progression, and the x-axis indicates months up to 36. D-Pd shows higher survival proportions over time. A table inset presents median progression-free survival and hazard ratio between groups.*

FDA Label Image

Darzalex 02

The packaging label for Darzalex Faspro injection contains daratumumab and hyaluronidase-fihj, available as 1800 mg and 30,000 Units per 15 mL vial for subcutaneous use only. The label includes detailed storage instructions, inactive ingredients, dosage form as a single-dose vial, and manufacturer information from Janssen Biotech, Inc. Additional warnings emphasize discarding unused portions and administering the injection over 3 to 5 minutes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.